Submitted for Publication: August 26, 2014; final revision received October 28, 2014; accepted October 31, 2014.
Published Online: January 15, 2015. doi:10.1001/jamaophthalmol.2014.5650.
Study concept and design: Hahn, Chung, Flynn, Huang, Kim, Mahmoud, Dugel.
Acquisition, analysis, or interpretation of data: Hahn, Chung, Flynn, Huang, Kim, Mahmoud, Sadda, Dugel.
Drafting of manuscript: Hahn, Dugel.
Critical revision of the manuscript for important intellectual content: Hahn, Chung, Flynn, Huang, Kim, Mahmoud, Sadda, Dugel.
Statistical analysis: Hahn, Flynn, Huang, Kim, Mahmoud, Dugel.
Administrative, technical, or material support: Chung.
Study supervision: Sadda, Dugel.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Chung reported consulting for Glaxo Smith Kline and receiving grant funding from Canon, both unrelated to the submitted work. Dr Huang reported receiving consulting agreements unrelated to the submitted work with Bausch & Lomb, Sequenom, Second Sight, Notal Vision, Lumoptik Eye, and BioFirst. Dr Kim reported receiving clinical trial funding unrelated to the submitted work from Regeneron and Genentech and research support from Optos, serving on the advisory board for Allergan and ThromboGenics, and receiving funding from an unrestricted grant from the Research to Prevent Blindness Inc. Dr Mahmoud reported roles on advisory boards unrelated to the submitted work with Alimera, Allergan, and Alcon. Dr Sadda reported receiving consulting agreements unrelated to the submitted work with Allergan, Genentech, Carl Zeiss Meditec, and Optos; grants and pending grants from Carl Zeiss Meditec, Optovue, and Optos; and royalties from Topcon Medical Systems. Dr Dugel reported receiving consulting agreements with Regeneron, consulting agreements unrelated to the submitted work with Abbott, Alcon, Allergan, Arctic DX, Alimera Sciences, Acucela, Digisight, Genentech, LUX, Macusight, Neovista, ORA, Ophthotech, and ThromboGenics, and stock or stock options with Arctic DX, Macusight, Neovista, Ophthotech, and Digisight. No other disclosures were reported.
Additional Contributions: The American Society of Retina Specialists Therapeutic Surveillance Committee thanks the reporting physicians who shared their experiences for the benefit of the greater ophthalmology community.
Additional Information: The authors are members of the American Society of Retina Specialists Therapeutic Surveillance Committee.